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Abstract 
Background: Patients with diabetes are prone to develop cardiac hypertrophy and more susceptible to myocardial 
ischemia–reperfusion (I/R) injury, which are concomitant with hyperglycemia‑induced oxidative stress and impaired 
endothelial nitric oxide (NO) synthase (eNOS)/NO signaling. Caveolae are critical in the transduction of eNOS/NO sign‑
aling in cardiovascular system. Caveolin (Cav)‑3, the cardiomyocytes‑specific caveolae structural protein, is decreased 
in the diabetic heart in which production of reactive oxygen species are increased. We hypothesized that treatment 
with antioxidant N‑acetylcysteine (NAC) could enhance cardiac Cav‑3 expression and attenuate caveolae dysfunction 
and the accompanying eNOS/NO signaling abnormalities in diabetes.
Methods: Control or streptozotocin‑induced diabetic rats were either untreated or treated with NAC (1.5 g/kg/day, 
NAC) by oral gavage for 4 weeks. Rats in subgroup were randomly assigned to receive 30 min of left anterior descend‑
ing artery ligation followed by 2 h of reperfusion. Isolated rat cardiomyocytes or H9C2 cells were exposed to low 
glucose (LG, 5.5 mmol/L) or high glucose (HG, 25 mmol/L) for 36 h before being subjected to 4 h of hypoxia followed 
by 4 h of reoxygenation (H/R).
Results: NAC treatment ameliorated myocardial dysfunction and cardiac hypertrophy, and attenuated myocardial 
I/R injury and post‑ischemic cardiac dysfunction in diabetic rats. NAC attenuated the reductions of NO, Cav‑3 and 
phosphorylated eNOS and mitigated the augmentation of O2
−, nitrotyrosine and 15‑F2t‑isoprostane in diabetic 
myocardium. Immunofluorescence analysis demonstrated the colocalization of Cav‑3 and eNOS in isolated cardio‑
myocytes. Immunoprecipitation analysis revealed that diabetic conditions decreased the association of Cav‑3 and 
eNOS in isolated cardiomyocytes, which was enhanced by treatment with NAC. Disruption of caveolae by methyl‑β‑
cyclodextrin or Cav‑3 siRNA transfection reduced eNOS phosphorylation. NAC treatment attenuated the reductions of 
Cav‑3 expression and eNOS phosphorylation in HG‑treated cardiomyocytes or H9C2 cells. NAC treatment attenuated 
HG and H/R induced cell injury, which was abolished during concomitant treatment with Cav‑3 siRNA or eNOS siRNA.
Conclusions: Hyperglycemia‑induced inhibition of eNOS activity might be consequences of caveolae dysfunction 
and reduced Cav‑3 expression. Antioxidant NAC attenuated myocardial dysfunction and myocardial I/R injury by 
improving Cav‑3/eNOS signaling.
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Background
Cardiovascular disease is a leading cause of morbidity 
and mortality especially in patients with diabetes mellitus 
(DM) [1]. Patients with DM are prone to develop multiple 
cardiovascular complications, including coronary heart 
disease, cardiac hypertrophy and heart failure [2]. Most 
diabetic heart failure etiology concerns ischemic heart 
diseases [e.g., myocardial ischemia/reperfusion (I/R) 
injury] and diabetic cardiomyopathy [3, 4]. The patho-
genesis of diabetic cardiomyopathy and myocardial I/R 
injury is very complicated, but much evidence indicates 
the involvement of excessive production of reactive oxy-
gen species (ROS) induced by metabolic disorders in dia-
betes [2, 5, 6]. Despite significant advances in laboratory 
researches and clinical trials of antioxidant treatment in 
the past decade, the underlying mechanisms by which 
hyperglycemia-induced oxidative stress exerts adverse 
effects in diabetic hearts are not yet fully understood.
Nitric oxide (NO), which is synthesized by a family of 
NO synthases (NOS) including neuronal, inducible, and 
endothelial NOS (n/i/eNOS), plays an important role in 
cardiovascular physiology and pathology [7]. The eNOS-
derived NO has been reported to inhibit the progres-
sion of myocardial infarction [8], ameliorate myocardial 
I/R injury [9] and left ventricular hypertrophy [10, 11], 
and prevent the onset of heart failure [12]. Moreover, 
NO can scavenge ROS and reduce detrimental effects of 
ROS [13, 14]. Therefore, regulation of the eNOS/NO and 
ROS balance is of importance in the progression of dia-
betic cardiomyopathy and myocardial I/R injury in dia-
betes. eNOS is constitutively expressed in the heart and 
enriched in cardiomyocyte caveolae [15, 16]. Caveolae 
serves as a platform in plasma membrane to modulate 
transduction pathways via signaling molecules docked 
within caveolins, and three integral isoforms of caveolins 
are identified in mammalian caveolae, termed caveolin 
(Cav) 1, 2 and 3. In the cardiovascular system, Cav-1 and 
Cav-2 are found in multiple cell types, whereas Cav-3 is 
mainly expressed in cardiac muscle cells and is essential 
for the formation of cardiomyocytes caveolae [17]. In 
cardiomyocytes, eNOS localizes to caveolae bound to 
Cav-3, and the co-localization of Cav-3 and eNOS may 
facilitate both eNOS activation and NO release for inter-
cellular signaling [18]. Therefore, Cav-3 is important for 
maintaining eNOS/NO signaling in the heart. Thus, any 
alteration of Cav-3 expression in diabetic condition may 
be implicated in the pathogenesis of diabetic cardio-
myopathy and myocardial I/R injury. This notion is sup-
ported by our previous findings that decreased Cav-3 
expression and cardiac NO bioavailability are detected 
in hearts from rats with chronic streptozotocin (STZ)-
induced diabetes [19, 20], which are associated with 
more serious myocardial I/R injury [19, 21]. However, 
it remains unclear whether or not excessive production 
of ROS mediated diabetic abnormalities is an independ-
ent manifestation of hyperglycemic injury or is linked to 
impaired Cav-3 expression and eNOS/NO signaling in 
diabetes. In the present study, we hypothesize hypergly-
cemia-induced oxidative stress promotes caveolae dys-
function and impairs Cav-3/eNOS signaling. Our data 
suggested that inhibition of excessive oxidative stress by 
N-acetylcysteine (NAC), an antioxidant which has been 
proven by us [22–26] and others [27, 28] to be effective 
in attenuating oxidative stress in diabetic hearts, could 
restore Cav-3 expression and improve eNOS/NO signal-
ing, which ultimately attenuate diabetic cardiomyopathy 
and myocardial I/R injury in diabetic rats.
Methods
Experimental animals and induction of diabetes
This study was carried out in accordance with the recom-
mendations in the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health (NIH 
Publication No. 80–23), and approved by Institutional 
Animal Care and Use Committee of Wuhan University. 
Male Sprague-Dwaley rats (260 ± 10 g, 7–8 weeks) were 
obtained from the Laboratory Animal Unit of Wuhan 
University. They were randomly assigned to the control 
group, diabetic group, and diabetic group treated with 
NAC. Diabetes was induced by a single tail vein injec-
tion of streptozotocin (STZ, Sigma, USA) at the dose of 
60 mg/kg under halothane anesthesia, while control rats 
were injected with equal volume citrate buffer alone. 
Three days after STZ injection, the rats with fasting 
plasma glucose levels  ≥16.7  mM measured by using a 
glucose analyzer (Beckman Instruments), were consid-
ered as diabetes and used for the experiments. One week 
after induction of diabetes, rats were treated by oral gav-
age with vehicle or NAC for 4 weeks at the dose of 1.5 g/
kg/day [23]. Rats in subgroups were proceeded to evalu-
ate cardiac function by echocardiography. After meas-
urement of plasma glucose and body weight, the rats 
were euthanized under deep anesthesia and the hearts 
were rapidly harvested and stored at −80  °C for further 
detection.
Cardiac function by echocardiography
Transthoracic echocardiography was performed non-
invasively at experiment termination with Vevo 770™ 
high-resolution imaging system equipped with a 
17.0  MHz transducer (RMV-716, Visual Sonics, Can-
ada), and left ventricular (LV) dimensions and LV dias-
tolic and systolic function were assessed by M-mode 
and Doppler echocardiography as we previously 
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described [20]. The heart rate (HR), left ventricular 
internal dimensions at end systole (LVIDs) and dias-
tole (LVIDd), left ventricular posterior wall dimen-
sions at end diastole (LVPWd) and systole (LVPWs), 
LV end-distolic volume (LVVd) and end-systolic 
volume (LVVs), left ventricular isovolumic relaxa-
tion time (IVRT), stroke volume (SV) and the ratio 
of the peak velocity of early (E) and late (A) diastolic 
filling (E/A) were monitored. Fractional shorting 
(FS,   %)  =  (LVIDd  −  LVIDs)/LVIDd  ×100  %, LVPW 
(%)  =  (LVPWs  −  LVPWd)/LVIDd  ×100  %, Ejection 
fraction (EF,  %) =  (LVVd − LVVs)/LVVd ×100 %. All 
derived measures by echocardiography were obtained 
by averaging the readings of three consecutive beats.
Haematoxylin and eosin (H‑E) staining and in situ DHE 
(dihydroethidium) staining of the left ventricle
Cardiomyocytes cross-sectional area was assessed by 
H-E stained paraffin-embedded sections of left ventricles 
(LV), and in situ levels of LV O2− production were deter-
mined by DHE staining, as we previously described [24]. 
A minimum of 150 cells per rat was chosen for analysis of 
cardiomyocytes cross-sectional area. The fluorescence of 
DHE-stained positive cells was calculated in each of five 
randomly selected fields.
Rat cardiomyocytes isolation
Adult rat cardiomyocytes were isolated and prepared via 
a modified method, as described [20]. Briefly, the rats 
were anesthetized and heparinized, and the hearts were 
rapidly removed and mounted on a Langendorff perfu-
sion apparatus. After enzymatic digestion for 20  min 
(min), the ventricle was gently teased into small pieces 
and filtered immediately to exclude undigested tissues, 
and then the cardiomyocytes were pelleted by grav-
ity for 10 min and resuspended with M199 medium for 
three times. After the final suspension, the cardiomyo-
cytes were incubated in low glucose (LG) (5.5 mmol/L), 
high glucose (HG) (25  mmol/L), mannitol/glucose 
(19.5  mmol/L mannitol plus 5.5  mmol/L glucose) or 
N-acetylcysteine (NAC, 1  mmol/L [26]) at 37  °C in 
Medium 199 (Gibco, Grand Island, NY) medium with 
selenium/insulin/transferring (Sigma-Aldrich, St. Louis, 
MO) containing various treatments for 36 h (h) accord-
ing to the previous study [20], in which high glucose 
duration for 36  h significantly induced cardiomyocytes 
injury and impaired Cav-3 expression.
Confocal immunofluorescence
The subcellular localization of Cav-3 and eNOS in car-
diomyocytes was inspected by confocal immunofluores-
cense, as described [20]. Briefly, isolated cardiomyocytes 
were plated on Matrigel precoated glass coverslips, 
incubated in Medium 199 for 36  h (h). The cells were 
fixed and blocked with 10  % goat serum and 1  % BSA, 
and then incubated with a mixture of rabbit against rat 
eNOS antibody (1:100; Santa Cruz Biotechnology) and 
mouse against rat Cav-3 antibody (1:50; Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Then, the cells were 
incubated for a mixture of Alexa Fluor 488 goat anti-
mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG 
(1:2000; Invitrogen, Carlsbad, CA, USA), and prepared 
for confocal laser scanning microscopic imaging with 
mounting medium containing DAPI (Vector Laborato-
ries, Burlingame, CA, USA).
Immunoprecipitation
Immunoprecipitation was performed as previously 
described [20]. Briefly, the isolated cardiomyocytes were 
cultured in LG or HG conditions with or without NAC 
treatment for 36 h. The cells were homogenized in lysis 
buffer and the protein concentration was measured by 
Bio-Rad Protein Assay kit. A total of 500 mg cell prepara-
tions were performed to immunoprecipitation with 2 mg 
Cav-3 primary antibody in the presence of 20 mL protein 
A/G plus-agarose. Then, the immunoprecipitates were 
denatured and subjected to analysis for eNOS expression 
by Western blot as described below.
Myocardial I/R injury model
After the completion of NAC treatment (5-weeks after 
the onset of diabetes), subgroup of the experimental rats 
was subjected to myocardial I/R injury as described pre-
viously [21, 29], in which rats were anaesthetized and 
subjected to myocardial I/R achieved by occluding the 
left anterior descending coronary artery for 30  min fol-
lowed by reperfusion for 2 h. Sham-operated rats under-
went the same surgical procedures without ligation. At 
the end of the reperfusion, myocardial infarct size of 
the experimental rats was measured using Evans Blue 
dye/2,3,5-triphenyltetrazolium chloride (TTC) staining 
as we described [29]. The unstained region by Evans blue 
dye was considered as the area at risk (AAR). The area 
unstained by TTC was identified as the infarcted tissue. 
Myocardial infarct size was expressed as a percentage of 
the AAR (%AAR). Hemodynamic changes of the experi-
mental rats subjected to myocardial I/R were monitored 
as we described [29]. Briefly, a saline-filled catheter was 
inserted into the left ventricle via an incision on the right 
common carotid artery and then connected to a pressure 
transducer. The left ventricular systolic pressure (LVSP), 
left ventricular maximum rate of increase of left ven-
tricular developed pressure (+dp/dt), maximum rate of 
decrease of left ventricular developed pressure (−dp/dt) 
and HR were monitored at 10 min before ischemia (base-
line) and 2 h after reperfusion.
Page 4 of 16Su et al. Cardiovasc Diabetol  (2016) 15:146 
siRNA studies in H9C2 cells and induction of hypoxia/
reoxygenation
Embryonic rat cardiomyocyte-derived cell line H9C2 
was maintained in DMEM (Dulbecco’s modified Eagle’s 
medium) containing 10  % FBS in a humidified atmos-
phere (5 % CO2) at 37  °C. Commercial Cav-3 siRNA or 
eNOS siRNA (Santa Cruz Biotechnology) was used for 
inhibition of Cav-3 expression according to the manu-
facturer’s protocol. After transfection with control, Cav-3 
siRNA or eNOS siRNA, cells were treated with N-ace-
tylcysteine (NAC, 1  mmol/L) in the condition of LG or 
HG for 36 h, then the cells was exposed to 4 h of hypoxia 
(1 % O2, 5 % CO2, 94 % N2) followed by 4 h of reoxygena-
tion (H/R). LDH (lactate dehydrogenase) release was 
measured to evaluate the extent of cellular injury using a 
cytotoxicity assay kit (Jiancheng Bioengineering Institute, 
China) according to the manufacturer’s instructions.
Determination of CK‑MB and 15‑F2t‑isoprostane
Serum CK-MB (creatine kinase-MB) levels, a major 
indicator of myocardial I/R injury, were measured in 
the arterial blood samples collected at the end of rep-
erfusion by enzyme immunoassay using a commercial 
ELISA kit (Elabscience Biotechnology) as we described 
[29]. 15-F2t-isoprostane (15-F2t-IsoP), a specific marker 
of oxidative stress [30], was measured using an EIA kit 
(Cayman chemical, Ann Arbor, MI, USA) as described 
previously [23]. The value of 15-F2t-IsoP in the heart tis-
sue was expressed as pg/mg protein.
Measurement of the levels of O2
−, NO and nitrotyrosine
O2− production in cardiac tissues or isolated cardio-
myocytes was assayed using lucigenin chemilumines-
cence method [31, 32]. Total protein concentration in 
the supernatant was determined by Bio-Rad Protein 
Assay kit. The supernatant samples were loaded with 
dark-adapted lucigenin (5  μM), then read in 96-well 
microplates using a luminometer (GloMax, Promega) 
with and without pretreatment with the NOS inhibitor 
L-NAME (100 μM [33]) for 30 min at room temperature. 
Light emission was recorded for 5 min and expressed as 
mean light units (MLU)/min/100  μg protein. NO con-
tent was determined using Lowry assay kit (Bio-Rad, CA, 
USA). The concentration of nitrites (NO2−) and nitrates 
(NO3−), stable end products of nitric oxide (NO), were 
determined by the Griess reaction, as described previ-
ously [34] NO levels were expressed as nmol/μg protein. 
The levels of myocardial nitrotyrosine in the collected 
supernatant were assayed by chemiluminescence detec-
tion using the Nitrotyrosine Assay Kit according to the 
manufacturer’s instructions (Millipore, USA). Myocar-
dial nitrotyrosine concentration was expressed as μg/mg 
protein.
Western blot analysis
Equal amounts of protein were separated via 7.5–12.5 % 
SDS-PAGE and subsequently transferred to PVDF mem-
brane for immunoblot analysis as described previously 
[23]. The membranes were blocked in 5 % no fat milk for 
2 h at room temperature, and then incubated overnight at 
4 °C with primary antibodies against Cav-3 (1:500, Santa 
Cruz Biotechnology), eNOS (1:1000, Cell Signaling Tech-
nology), p-eNOS (Ser1177) (1:500, Cell Signaling Tech-
nology). After being washed with TBST, the membranes 
were incubated with proper secondary horseradish per-
oxidase (HRP)-conjugated antibodies (1:5000–1:10,000, 
Cell Signaling Technology), and developed with 
enhanced chemiluminescence reagent (GE Healthcare, 
USA). The membranes were subsequently reblotted for 
GAPDH (1:2000, Cell Signaling Technology), and the 
results were normalized to GAPDH to correct for load-
ing. Data are presented as percent change relative to the 
measurement in control rats.
Statistical analysis
All the values are expressed as mean  ±  SD GraphPad 
Prism software program (GraphPad Software Inc., San 
Diego, CA, USA) was used for statistical analysis. Com-
parison between multiple groups was made with one-way 
analysis of variance (ANOVA) followed by Tukey’s test 
for multiple comparisons, or two-way repeated-meas-
ures ANOVA followed by Bonferroni’s post hoc test in 
grouped values. Significance was defined as P < 0.05.
Results
Antioxidant NAC attenuated cardiac hypertrophy 
and myocardial dysfunction in diabetic rats
At the end of treatment period, the diabetic rats without 
NAC treatment had significantly elevated plasma glu-
cose and reduced heart weight compared with control 
rats, which was not altered by 4 weeks of treatment with 
NAC. However, the decreased body weight and increased 
ratio of heart weight to body weight in diabetic rats, an 
indirect index of myocardial hypertrophy, was signifi-
cantly reversed by NAC treatment (Table  1). We fur-
ther assessed the cardiomyocyte cross-sectional area by 
H-E staining in LV sections. The cross-sectional area in 
untreated diabetic rats (452.5  ±  63.7  μm2) was signifi-
cantly bigger than that in control rats (301.5 ± 41.2 μm2), 
NAC treatment (338.8 ± 47.1 μm2) significantly attenu-
ated this alteration of cross-sectional area in diabetic rats, 
indicating antioxidant treatment with NAC can attenuate 
cardiomyocyte hypertrophy in diabetes.
We further examined the effects of NAC on cardiac 
function by echocardiography. Parameters in FS (Fig. 1b), 
FLVPW (Fig. 1c) and EF (Fig. 1d) did not significantly dif-
fer among all the experimental groups. This means that 
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the systolic function was not yet affected in 5  weeks of 
diabetic rats. Further, diabetic rats induced by STZ for 
5  weeks manifested decreased heart rate (HR) (Fig.  1a) 
and reduced ratio of peak velocity of early and late dias-
tolic filling (E/A) (Fig.  1f ), accompanied with increased 
left ventricular isovolumic relaxation time (IVRT) 
(Fig.  1e), which indicated diastolic function in early dia-
betic heart was impaired, and this is consistent with the 
characteristics of diabetic cardiomyopathy [35–37]. NAC 
treatment for 4 weeks restored the levels of E/A and IVRT, 
but did not significantly increase HR (Fig. 1a, e and f ).
Effects of antioxidant NAC on the levels of 15‑F2t‑IsoP, NO, 
nitrotyrosine and O2
− in diabetic heart tissues
Oxidative stress plays an important role in the patho-
genesis of diabetic complication. In the present study, 
we detected myocardial O2− production in LV sections 
stained by DHE. The number of DHE-stained positive 
cells in the hearts of diabetic rats was much more than 
that in control rats, which was attenuated by NAC treat-
ment (Fig.  2a). We then measured the levels of 15-F2t-
IsoP, a specific marker of oxidative stress. As shown in 
Fig.  2b, the level of 15-F2t-IsoP in diabetic group was 
significantly higher than that of the control group, which 
was attenuated by NAC treatment.
We also detected the levels of NO, nitrotyrosine and 
O2− production in homogenized heart tissues. As is 
shown in Fig. 2c–e, diabetes significantly decreased NO 
levels, and increased nitrotyrosine and O2− production 
in heart tissues. NAC treatment for 4  weeks attenuated 
or blocked all these alterations. Further studies revealed 
that diabetes induced increase of O2− levels was blocked 
by the NOS inhibitor L-NAME (100 μM) (Fig. 2e), indi-
cating a NOS-dependent mechanism for O2− accumu-
lation or “eNOS uncoupling”. To confirm this, we also 
detected the levels of NO and O2− production in isolated 
cardiomyocytes. As shown in Fig. 2f, g, the levels of NO 
were significantly decreased, and O2− production was 
significantly increased in isolated cardiomyocytes from 
diabetic rats as compared with that from control rats, 
NAC treatment reversed these changes. Similar to the 
treatment effects of NOS inhibitor L-NAME in homog-
enized heart tissues, the increased O2− production was 
also blocked by L-NAME in isolated cardiomyocytes.
Effects of NAC treatment on myocardial expression 
of Cav‑3 and p‑eNOS in diabetic rats, as well as their 
association in isolated cardiomyocytes
We previously reported decreased Cav-3 expression (a 
muscle-specific marker of caveolae [17]) and reduced 
phosphorylation of eNOS in the hearts of diabetic rats 
[20], which may be attributable to reduced tolerance of 
diabetic heart to myocardial I/R [7, 21]. Therefore, our 
present study examined whether NAC treatment could 
reverse these changes in the diabetic hearts. As shown 
in Fig. 3a, b, NAC significantly attenuated the reductions 
of cardiac Cav-3 and p-eNOS expression in diabetic rats. 
We next examined the association of Cav-3 and eNOS in 
isolated cardiomyocytes. As shown in Fig. 3c, the confo-
cal immunofluorescence staining showed the colocaliza-
tion between eNOS and Cav-3 during basal conditions 
in the cell membrane (indicated by scant yellow punc-
tate staining of the cell periphery) of insolated cardio-
myocytes from non-diabetic rats, which may facilitate 
the transduction of eNOS/NO signaling [18]. To con-
firm this, we also did immunoprecipitation experiments 
in isolated rat cardiomyocytes from various groups. A 
mount of eNOS remained constitutively associated with 
Cav-3 during basal conditions, while the diabetic con-
ditions decreased the association of eNOS with Cav-3, 
which was restored by NAC treatment (Fig. 3d).
Hyperglycemia‑induced inhibition of eNOS activation 
involves caveolae dysfunction and reduced Cav‑3 
expression, which contributes to eNOS uncoupling
Given cardiomyocytes caveolae is necessary for eNOS 
signaling [18], we determined whether caveolae dysfunc-
tion is crucial in hyperglycemia-induced inhibition of 
eNOS activation. In our preliminary studies, the cav-3 
expression and eNOS phosphorylation at ser1177 were not 
significantly affected by NAC or mannitol in isolated car-
diomyocytes or H9C2 cells (data not shown). As shown 
in Fig. 4a, in the presence of methyl-b-cyclodextrin (CD, 
10  μmol/L), a disrupter of cholesterol-rich caveolae 
[38], the phosphorylation of eNOS was reduced signifi-
cantly in cardiomocytes during LG conditions, suggest-
ing that eNOS activation required caveolae under basal 
conditions. Disruption of caveolae by CD slightly but 
did not further significantly exaggerate the reduction 
Table 1 General characteristics of experimental group
Control (C) or STZ-induced diabetic (D) rats were either untreated or treated with 
N-acetylcysteine (1.5 g/kg/day, D + NAC) by oral gavage for 4 weeks. All the 
results are expressed as mean ± SD, n = 8. Differences in general characteristics 
among the three groups were determined by using one-way ANOVA followed 
by Tukey’s test
* P < 0.05
** P < 0.01 vs. C group
# P < 0.05 vs. D group
C D D + NAC
Plasma glucose (mM) 6.41 ± 0.61 29.12 ± 5.13** 25.86 ± 2.76**
Heart weight (g) 1.62 ± 0.23 1.21 ± 0.17* 1.38 ± 0.20*
Body weight (g) 450.5 ± 20.3 263.7 ± 17.6* 362.5 ± 24.2*#
Heart weight/body‑
weight (mg/g)
3.59 ± 0.09 4.58 ± 0.12* 3.81 ± 0.11#
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of eNOS phosphorylation in HG-treated cardiomyo-
cytes. NAC treatment restored eNOS phosphorylation 
in HG-treated cardiomyocytes, but this effect was abol-
ished during concomitant CD treatment. We next inves-
tigated whether hyperglycemia-induced inhibition of 
eNOS activation might be associated with reduced cav-3 
expression. As shown in Fig. 4b, H9C2 cells treated with 
rat-specific Cav-3 siRNA exhibited about 57  % reduc-
tion of Cav-3 expression during both LG and HG con-
ditions. This reduction of Cav-3 expression resulted in 
Fig. 1 N‑acetylcysteine treatment attenuated myocardial dysfunction in diabetic rats. Control (C) or STZ‑induced diabetic rats were either untreated 
(D) or treated with antioxidant N‑acetylcysteine (1.5 g/kg/day, NAC) by oral gavage for 4 weeks. All the rats were lightly anesthetized and performed 
transthoracic echocardiography. a–f Heart rate (a), fractional shortening (FS) (b), fractional left ventricular posterior wall thickening (FLVPW) (c), 
ejection fraction (EF) (d), left ventricular isovolumic relaxation time (IVRT) (e), and the ratio of peak velocity of early and late diastolic filling (E/A) 
(f). All the results are expressed as mean ± SD, n = 7 per group. Differences were determined by using one‑way ANOVA followed by Tukey’s test. 
*P < 0.05 vs. all the other groups
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further reduced eNOS phosphorylation in both LG- and 
HG-treated cells (Fig. 4c). NAC treatment restored Cav-3 
expression and eNOS phosphorylation in HG-treated 
cells, which was abolished during concomitant treatment 
with Cav-3 siRNA (Fig.  4b, c). Therefore, the beneficial 
effects of NAC on eNOS phosphorylation in HG-treated 
cells require normal caveolae and Cav-3 expression.
We then examined the treatment effects of Cav-3 
siRNA on the levels of O2− and NO in HG-treated H9C2 
cells. As shown in Fig. 4d, e, HG significantly increased 
the levels of O2− and decreased the levels of NO com-
pared to LG. Cav-3 siRNA further increased these 
changes of O2− and NO. NAC treatment significantly 
attenuated HG-induced increase of O2− production and 
decrease of NO levels. While these beneficial effects of 
NAC were abolished by transfection of Cav-3 siRNA. 
These results collectively suggest that reduced Cav-3 
expression contributes to eNOS uncoupling.
Antioxidant NAC attenuates myocardial I/R injury 
and post‑ischemic cardiac dysfunction in diabetic rats
We next investigate the treatment effects of NAC on 
myocardial I/R injury in diabetes. As shown in Fig.  5a, 
the rats subjected to myocardial I/R in untreated diabetic 
showed larger infarct size than that in non-diabetic con-
trol rats, which was attenuated by NAC treatment. We 
also measured the biochemical markers of myocardial 
I/R injury and oxidative stress in the experiment rats. 
Compared with corresponding sham-operated rats, the 
levels of plasma CK-MB, plasma 15-F2t-IsoP and cardiac 
15-F2t-IsoP were significantly increased in rats under-
went myocardial I/R insult (Fig.  5b–d). Under baseline 
conditions, diabetes-induced increase of both plasma 
and cardiac 15-F2t-IsoP was significantly attenuated by 
NAC treatment, but no significant difference was shown 
in plasma CK-MB among control, untreated and NAC 
treated diabetic rats. Whereas in the rats underwent 
myocardial I/R insult, the untreated diabetic rats dem-
onstrated significantly increased the levels of plasma 
CK-MB, plasma 15-F2t-IsoP and cardiac 15-F2t-IsoP as 
compared with control rats, and all these changes were 
attenuated by NAC treatment. We also monitored hemo-
dynamics in experimental rats. As shown in Table 2, the 
levels of HR, LVSP, +dp/dt and −dp/dt in diabetic rats 
at baseline were significantly reduced as compared with 
control rats, and NAC could significantly increase +dp/
dt and −dp/dt levels as compared with untreated dia-
betic rats. However, NAC treatment slightly but not 
significantly increased the levels of HR and LVSP in 
diabetic rats. After 2 h of reperfusion, the levels of HR, 
LVSP, +dp/dt and −dp/dt in all experimental rats were 
significantly decreased as compared with that at baseline, 
indicating cardiac dysfunction following myocardial I/R 
insult. The reduction of HR, LVSP, +dp/dt and −dp/dt 
in diabetic rats underwent 2 h of reperfusion was signifi-
cantly attenuated by NAC treatment.
NAC attenuates HG and hypoxia/reoxygenation (H/R) 
induced cell injury, which requires intact Cav‑3/eNOS 
signaling
We further determined the treatment effects of NAC 
on cultured cardiomyocytes and H9C2 cells exposed 
to H/R insult during LG and HG conditions. NAC 
and mannitol had no effects on cell injury measured 
by LDH and 15-F2t-IsoP during basal conditions (data 
not shown). As shown in Fig. 6, both the levels of LDH 
release and 15-F2t-IsoP in H/R-treated cardiomyocytes 
and H9C2 cells in various groups were significantly 
higher than that in the corresponding groups under 
normoxia conditions. HG stimulation significantly 
increased the levels of LDH release and 15-F2t-IsoP as 
compared with that in the LG group in both normoxia 
and H/R conditions, which were significantly attenu-
ated by NAC treatment. To further investigate the 
role of Cav-3/eNOS in the beneficial effects of NAC in 
in  vitro studies, the H9C2 cells were transfected with 
Cav-3 siRNA or eNOS siRNA during LG or HG con-
ditions and treated with or without H/R insult. Similar 
to the effects of Cav-3 siRNA transfection on prevent-
ing Cav-3 expression (Fig.  4b), eNOS siRNA inhibited 
both the expression of total eNOS and eNOS phospho-
rylation at ser1177 in LG and HG conditions (data not 
shown). As shown in Fig. 6c, d, either Cav-3 siRNA or 
eNOS siRNA significantly increased LDH release and 
15-F2t-IsoP levels in LG or HG conditions in H9C2 
cells subjected to normoxia or H/R. Additionally, the 
(See figure on previous page.) 
Fig. 2 Effects of N‑acetylcysteine treatment on the levels of 15‑F2t‑IsoP, NO, nitrotyrosine and O2
− in diabetic myocardium, as well as NO and O2
− 
levels in isolated cardiomyocytes. Control (C) or STZ‑induced diabetic rats were either untreated (D) or treated with antioxidant N‑acetylcysteine 
(1.5 g/kg/day, NAC) by oral gavage for 4 weeks,and adult rats cardiomyocytes were isolated and prepared. a–e In situ O2
− production in LV sections 
stained by DHE (a), myocardial levels of 15‑F2t‑IsoP (b), NO (c), nitrotyrosine (d) and O2
− in the absence and presence of L‑NAME (e); f, g cardiomyo‑
cytes levels of NO (f) and O2
− (g) production in the absence and presence of L‑NAME. All the results are expressed as mean ± SD, n = 7. Differences 
of O2
− in the absence and presence of L‑NAME were determined by using two‑way repeated‑measures ANOVA followed by Bonferroni’s post hoc 
test, the others were determined by using one‑way ANOVA followed by Tukey’s test. *P < 0.05 vs. all the other groups. MLU, mean light unit
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concomitant treatment with Cav-3 siRNA or eNOS 
siRNA reversed NAC-mediated reduction in HG-
induced LDH release and 15-F2t-IsoP production, 
indicating the beneficial effects of NAC on decreasing 
post-hypoxic cell injury require intact Cav-3/eNOS 
signaling.
Discussion
In the present study, we have demonstrated that hyper-
glycemia-induced oxidative stress is accompanied with 
reduced Cav-3 expression and eNOS activation in dia-
betic hearts, which is consistent with our previous find-
ings [20]. The advancement of the current study is that 
Fig. 3 Expression of Cav‑3 and p‑eNOS in diabetic hearts, and their association in isolated cardiomyocytes. a, b Representative western blot of 
Cav‑3 expression with glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) as loading control (a) and p‑eNOS expression compared with total 
eNOS expression (b) in myocardium from the control (c), diabetic (d) and N‑acetylcysteine‑treated (1.5 g/kg/day, NAC) rats. c Confocal laser micro‑
scopic image of isolated cardiomyocytes from non‑diabetic rats underwent standard immunofluorescence staining with Cav‑3 and eNOS. d The 
lysates of isolated rat cardiomyocytes from various groups containing equal amount of total protein were subjected to immunoprecipitation (IP) 
with Cav‑3 antibody (Ab) and analyzed by immunoblot (IB) with eNOS and Cav‑3 antibody. All the results are expressed as mean ± SD, n = 7. Differ‑
ences were determined by using one‑way ANOVA followed by Tukey’s test. *P < 0.05 vs. all the other groups
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Fig. 4 Expression of p‑eNOS and Cav‑3 in cultured cardiomyocytes and H9C2 cells after various treatment in LG (5.5 mmol/L) and HG (25 mmol/L) 
conditions. a Representative western blot of p‑eNOS (Ser1177) in comparison with total eNOS expression in cardiomyoytes exposed to HG in the 
presence of N‑acetylcysteine (NAC, 1 mmol/L) or methyl‑b‑cyclodextrin (CD, 10 μmol/L); b–e Representative western blot of Cav‑3 (b) and p‑eNOS 
(Ser1177) (c), and levels of O2
− (d) and NO (e) in H9C2 cells transfected with Cav‑3 siRNA or treated with NAC (1 mmol/L). All the results are expressed 
as mean ± SD, n = 7. Differences were determined by using one‑way ANOVA followed by Tukey’s test. #P < 0.05 vs. corresponding group without 
siRNA treatment, *P < 0.05 vs. all the other groups
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Fig. 5 N‑acetylcysteine attenuated myocardial ischemia–reperfusion (I/R) injury in diabetic rats. Control (C) or STZ‑induced diabetic rats were either 
untreated (D) or treated with antioxidant N‑acetylcysteine (1.5 g/kg/day, NAC) by oral gavage for 4 weeks. Then the rats were anaesthetized and 
subjected to myocardial I/R achieved by occluding the left anterior descending coronary artery for 30 min followed by reperfusion for 2 h. Sham‑
operated rats underwent the same surgical procedures without ligation. a–d infarct size (a), CK‑MB (b), plasma 15‑F2t‑Isoprostane (15‑F2t‑IsoP, c), 
and cardiac 15‑F2t‑IsoP (d). All the results are expressed as mean ± SD, n = 7. Differences of infarct size among the groups were determined by 
using one‑way ANOVA followed by Tukey’s test, the others were determined by using two‑way repeated‑measures ANOVA followed by Bonferroni’s 
post hoc test. *P < 0.05 vs. the other groups in sham or I/R conditions
Table 2 Hemodynamics at baseline and 2 h of reperfusion in experimental rats
Control (C), diabetic (D) and N-acetylcysteine-treated diabetic rats (1.5 g/kg/day, D+NAC) were subjected to 30 min (min) of left anterior descending coronary artery 
occlusion followed by reperfusion for 2 h (h). The heart rate, left ventricular systolic pressure (LVSP), left ventricular maximum rate of increase of left ventricular 
developed pressure (+dp/dt) and maximum rate of decrease of left ventricular developed pressure (−dp/dt) were monitored at 10 min before ischemia (baseline) and 
2 h after reperfusion. All the results are expressed as mean ± SD, n = 8. Differences in hemodynamics at baseline and 2 h of reperfusion were determined by using 
two-way repeated-measures ANOVA followed by Bonferroni’s post hoc test
* P < 0.05
** P < 0.01 vs. their corresponding baseline
# P < 0.05 vs. their corresponding C group
$ P < 0.05 vs. their corresponding D group
Heart rate (bpm) LVSP (mmHg) +dp/dt (mmHg/s) −dp/dt (mmHg/s)
Baseline (10 min before ischemia)
C 374 ± 14 122 ± 7 6735 ± 643 4839 ± 612
D 313 ± 12# 103 ± 5# 5121 ± 520# 3670 ± 507#
D + NAC 328 ± 15# 114 ± 6 6355 ± 437$ 4635 ± 463$
2 h reperfusion
C 287 ± 11** 91 ± 5** 4658 ± 486* 3240 ± 447*
D 220 ± 13**# 64 ± 4**# 2476 ± 379*# 2134 ± 384*#
D + NAC 235 ± 15**# 87 ± 4**$ 3980 ± 424*$ 3102 ± 337*$
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hyperglycemia-induced inhibition of eNOS activation is 
associated with caveolae dysfunction and reduced Cav-3 
expression. Treatment with antioxidant NAC for 4 weeks 
attenuates diabetic cardiomyopathy and reduces myocar-
dial I/R injury, possibly through improving Cav-3/eNOS/
NO signaling. Furthermore, NAC treatment decreases 
15-F2t-IsoP, O2− and nitrotyrosine formation. The 
L-NAME-inhibited accumulation of O2− suggests the 
presence of eNOS or NOS uncoupling, which is consist-
ent with reduced cardiac levels of NO, p-eNOS (Ser1177). 
To our knowledge, this is the first study to explore the 
relationship between Cav-3 and eNOS in cardiomyocytes 
exposed to hyperglycemia and the effectiveness of anti-
oxidant treatment.
Treatment effects of NAC on diabetic cardiomyopathy 
and myocardial I/R injury
NAC is a thiol-containing radical scavenger and glu-
tathione precursor, thus it is widely used as an antioxi-
dant to remove ROS. Several studies have demonstrated 
that NAC may attenuate the myocardial damage by pro-
tecting cardiomyocytes from cell death [39], and NAC 
also has been proven to be effective in attenuating dia-
betic cardiac complications [22–28]. NAC when given 
at 0.5  g/kg/day for 3  months could partially attenuate 
hyperglycemia-induced myocardial oxidative stress and 
cardiac cell death in diabetic rats [40]. In comparison, 
NAC given at 1 g/kg/day, when treatment was started at 
an earlier phase and for a longer duration may be more 
Fig. 6 LDH release and 15‑F2t‑IsoP levels in cultured cardiomyocytes and H9C2 cells subjected to HG stimulation and hypoxia/reoxygenation (H/R) 
insult. Isolated cardiomyocytes from non‑diabetic rats were treated with or without N‑acetylcysteine (NAC, 1 mmol/L) during LG (5.5 mmol/L) or HG 
(25 mmol/L) conditions for 36 h, or H9C2 cells were transfected with Cav‑3 siRNA or eNOS siRNA and treated with or without NAC during LG and HG 
conditions, then exposed to 4 h of hypoxia followed by 4 h of reoxygenation. a–d LDH release (a) and 15‑F2t‑IsoP (b) in cultured medium of cardio‑
myocytes, and LDH release (c) and 15‑F2t‑IsoP (d) in cultured medium of H9C2 cells. All the results are expressed as mean ± SD, n = 7. Differences 
were determined by using two‑way repeated‑measures ANOVA followed by Bonferroni’s post hoc test. *P < 0.05 vs. the other groups in normoxia or 
H/R conditions
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effective in reducing ROS generation and fibrosis and 
improving cardiac function in diabetic mice [41]. In addi-
tion, NAC when administrated at the dose of 1.5  g/kg/
day for 4 weeks could attenuate diabetes-induced cardiac 
damage [22–24] and myocardial I/R injury [25, 26]. In 
our preliminary studies, we have treated the diabetic rats 
with low (0.5  g/kg/day), medium (1  g/kg/day) and high 
dose (1.5 g/kg/day) of NAC for 4 weeks (data not shown), 
but only the high dose of NAC could significantly attenu-
ated diabetic cardiomyopathy and myocardial I/R injury, 
so the high dose of NAC was chosen for ensuring mecha-
nistic exploration in the present study.
Early diabetic cardiomyopathy is characterized by left 
ventricular diastolic dysfunction, reduced contractil-
ity and prolonged diastole [35, 42]. In the present study, 
diabetes decreased the ratio of E/A and increased left 
ventricular IVRT, but did not alter FS, FLVPW and EF 
as assessed by echocardiography, indicating myocardial 
diastolic function rather than systolic function is mainly 
impaired in the early STZ-induced diabetic rats, and 
this myocardial dysfunction was attenuated by antioxi-
dant NAC treatment. It has been shown that NAC could 
decrease ROS levels in the fetal hearts and prevent the 
development of congenital heart disease in the offspring 
of pregestational diabetes [43] and attenuate the devel-
opment of cardiac fibrosis and remodeling in a mouse 
model of heart failure [44]. Our present study showed 
that NAC treatment attenuated diabetes-induced myo-
cardial hypertrophy evidenced by decreased ratio of heart 
weight to body weight and cardiomyocyte cross-sectional 
area. Similar to our study, chronic administration of 
sepiapterin and L-citrulline to increase eNOS activity 
preserves cardiac function and attenuates diabetic cardi-
omyopathy and myocardial I/R injury [45]. In the present 
study, the infarct size and CK-MB in untreated diabetic 
rats is higher than control rats, indicating diabetic rats 
are less tolerant to myocardial I/R injury, which is con-
sistent with our previous study [29]. NAC treatment 
attenuated the reduction of HR, LVSP, +dp/dt and −dp/
dt in diabetic rats underwent 2  h of post-ischemic rep-
erfusion. Further, NAC treatment attenuated plasma and 
cardiac 15-F2t-IsoP (a specific marker of oxidative stress 
[30]) in diabetic rats both in sham and myocardial I/R 
conditions, and reduced infarct size and CK-MB levels in 
diabetic rats subjected to myocardial I/R insult.
Role of hyperglycemia‑induced oxidative stress in eNOS 
uncoupling
It is well documented that diabetes-induced cardio-
vascular diseases are associated with hyperglycemia-
induced oxidative stress [2, 5, 6]. Excessive production 
of ROS may lead to impaired eNOS/NO signaling [7, 
46], which is involved in diabetic cardiomyopathy and 
myocardial I/R injury in diabetic conditions [45, 47, 48]. 
In STZ-induced diabetic rats, we found increased car-
diac 15-F2t-IsoP, nitrotyrosine and ROS production 
were concomitant with decreased eNOS phosphoryla-
tion at Ser1177 and NO levels. Our findings that diabetes 
induced increase of O2− levels was blocked by the NOS 
inhibitor L-NAME in myocardial tissues and isolated car-
diomyocytes, indicate the presence of eNOS and/or NOS 
uncoupling in diabetic heart, which is in line with a pre-
vious study [49]. Further studies showed that inhibition 
of Cav-3 expression by transfection with Cav-3 siRNA 
increased O2− production, LDH release and 15-F2t-Iso-
prostane, and decreased eNOS activation and NO levels. 
This is in keeping with findings from a recent study show-
ing that eNOS uncoupling is involved in caveolae dys-
function [50]. Furthermore, treatment of diabetes with 
antioxidant NAC reduced cardiac 15-F2t-IsoP, nitroty-
rosine and O2− production, and enhanced the protein 
expressions of Cav-3 and eNOS and their association, 
and increased eNOS phosphorylation and NO levels to 
levels comparable to that in the control rats. Thus, sup-
pression of hyperglycemia-induced oxidative stress may 
restore eNOS activity and Cav-3 expression in diabetic 
hearts, and restoring the Cav-3 expression or increasing 
the association of eNOS and Cav-3 may attenuate eNOS 
uncoupling.
Role of Cav‑3/eNOS signaling in diabetic cardiomyopathy 
and myocardial I/R injury
Although the precise mechanisms by which hyperglyce-
mia-induced inhibition of eNOS activity causes adverse 
effects in diabetic myocardium are not fully clear, the 
decreased expression of Cav-3, which is simultaneously 
stimulated by hyperglycemia in diabetes [19, 20], might 
be a major factor. The diabetes-induced decrease of Cav-3 
expression may lead to caveolae dysfunction, which plays 
a vital role in affecting eNOS activity in diabetic hearts. 
This is well supported by our immunofluorescence stud-
ies demonstrating the colocalization of Cav-3 and eNOS 
in isolated cardiomyocytes during basal conditions. 
Immunoprecipitation experiments showed that diabetic 
conditions decreased the association of Cav-3 and eNOS 
in isolated cardiomyocytes, which was increased by NAC 
treatment. Caveolae disruption by methyl-β-cyclodextrin 
suppressed eNOS phosphorylation in isolated cardiomy-
ocytes, and Cav-3 knockdown by siRNA prevented eNOS 
phosphorylation in H9C2 cells. These collectively suggest 
that caveolae or Cav-3 is required for eNOS activation in 
cardiomyocytes. NAC treatment attenuated HG-induced 
decrease of eNOS phosphorylation in isolated cardiomy-
ocytes or H9C2 cells, but these effects of NAC were abol-
ished in the presence of methyl-β-cyclodextrin and Cav-3 
siRNA. This indicates that NAC restores eNOS activity 
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possibly through improving Cav-3 expression or cave-
olae function. To our knowledge, this is the first study to 
provide direct evidence to demonstrate the relationship 
between decreased eNOS activity and caveolae dysfunc-
tion or reduced Cav-3 expression in cardiomyocytes and 
their link to hyperglycemia-induced oxidative stress.
Cav-3 is a major type of the caveolin family proteins 
in cardiac myocytes to form cardiomyocyte caveolae 
[17], which serve as a platform in the plasma membrane 
to modulate transduction pathways via signaling mol-
ecules docked within caveolins. It has been shown that 
both caveolae and caveolin-3 are critical for exendin-4 
induced protection of the heart from I/R injury [51]. 
Heterozygous Cav-3 mice show increased susceptibil-
ity to palmitae-induced insulin resistance [52], and loss 
of Cav-3 expression results in diabetic cardiomyopathy 
[53]. Diabetes-induced decrease of Cav-3 expression may 
lead to the reduced tolerance to myocardial I/R injury 
[19, 21]. Additionally, Cav-3 overexpression attenuates 
cardiac hypertrophy [54] and induces endogenous car-
diac protection from myocardial I/R injury [55]. This 
indicates that enhancing Cav-3 expression is beneficial 
to attenuate diabetic cardiomyopathy and myocardial 
I/R injury. In the present study, HG exposure for 36  h 
decreased Cav-3 expression in isolated cardiomyocytes 
or H9C2 cells, which were consistent with deceased 
Cav-3 in hearts from 5 weeks duration of diabetes. NAC 
treatment-induced restoration of Cav-3 expression atten-
uated diabetic cardiomyopathy and myocardial I/R injury 
in in vivo studies, and reduced HG and H/R induced cell 
injury in in vitro studies. However, the beneficial effects 
of NAC in H9C2 cells were abolished during concomi-
tant treatment with Cav-3 siRNA or eNOS siRNA, sug-
gesting the beneficial effects of NAC on diabetic hearts 
are achieved through Cav-3/eNOS signaling. These find-
ings may have clinical implications in developing thera-
pies to incorporate alternative antioxidant treatment and 
improving Cav-3/eNOS/NO signaling in combating dia-
betic cardiomyopathy and myocardial I/R injury.
Conclusions
In summary, the results of current study demonstrate 
that hyperglycemia-induced inhibition of eNOS activ-
ity is associated with caveolae dysfunction and reduced 
Cav-3 expression in diabetic hearts. Antioxidant NAC 
attenuates myocardial dysfunction and myocardial I/R 
injury by improving Cav-3/eNOS/NO signaling. Our 
data suggest that antioxidant treatment and improving 
Cav-3/eNOS signaling may be useful approaches for cor-
recting diabetes-induced abnormalities. However, fur-
ther studies will be needed to investigate the underlying 
mechanisms using cardiac specific Cav-3 overexpression 
or Cav-3 knockout mice.
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